Growth through acquisitions SPI Pharma recently completed the acquisition of Elementis Specialties to expand into the digestive health market, presenting an opportunity to cross-sell excipients and adjuvants to Elementis’ existing customer base and to onboard new customers seeking digestive health solutions.

Vaccine adjuvant expansion With the launch of QS-21 GH in collaboration with Q-VANT Biosciences, SPI Pharma is extending its adjuvant capabilities for vaccines, signaling potential demand from biopharma developers seeking advanced vaccine formulations.

Strategic collaborations Historical partnerships to develop advanced adjuvant systems (notably with Inimmune) indicate a proven pathway to co-develop innovative formulations, suggesting outreach to biotech and pharma firms pursuing next-generation adjuvants and delivery platforms.

Broad product platform A long-standing portfolio of functional excipients, active ingredients, and the S-Tab platform enables selling arguments around formulation flexibility, direct compression tablets, and disintegrating tablets, appealing to manufacturers aiming to optimize manufacturing efficiency.

Global lifecycle potential With a global technical team and a track record of high-quality standards, SPI Pharma can target multinational contract manufacturers and generic players seeking reliable excipients and adjuvants across multiple regions, driving expansion in regulated markets.